Eli Lilly Buys Cancer Therapy And Announces Timing Of Weight Loss Pill
Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2.5 billion U.S. in cash. Eli Lilly is purchasing Scorpion’s experimental oral therapy called “STX-478,
Global pharmaceutical company Eli Lilly's (LLY) preliminary 2024 revenue missed expectations on lower-than-expected sales of ...
24/7 Wall St. on MSN19h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback